Recent Advances in the Synthesis and Analysis of Atorvastatin and its Intermediates


Cite item

Full Text

Abstract

:Atorvastatin, a lipid-lowering drug that is widely used in the treatment of cardiovascular diseases, has significant clinical significance. This article focuses on the synthetic procedures of atorvastatin, including Paal-Knorr synthesis and several new synthetic strategies. It also outlines chemical and chemo-enzymatic methods for synthesizing optically active side chain of atorvastatin. In addition, a comprehensive overview of the analytical monitoring techniques for atorvastatin and its metabolites and impurities is reported, alongside a discussion of their strengths and limitations.

About the authors

Shu-Fang Li

Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology

Email: info@benthamscience.net

Wei Zhang

Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology

Email: info@benthamscience.net

Wen Zhang

Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology

Email: info@benthamscience.net

An Huang

Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology

Email: info@benthamscience.net

Jia-Qi Zhu

Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology

Email: info@benthamscience.net

Ya-Jun Wang

Key Laboratory of Bioorganic Synthesis of Zhejiang Provinceng Province, College of Biotechnology and Bioengineering, College of Biotechnology and Bioengineering, Zhejiang University of Technology

Author for correspondence.
Email: info@benthamscience.net

Yu-Guo Zheng

Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology

Email: info@benthamscience.net

References

  1. White, A.A. Mapping and geographic display of data. Stat. Med., 1995, 14(5-7), 697-699. doi: 10.1002/sim.4780140529 PMID: 7540768
  2. Townsend, N.; Kazakiewicz, D.; Lucy Wright, F.; Timmis, A.; Huculeci, R.; Torbica, A.; Gale, C.P.; Achenbach, S.; Weidinger, F.; Vardas, P. Epidemiology of cardiovascular disease in Europe. Nat. Rev. Cardiol., 2022, 19(2), 133-143. doi: 10.1038/s41569-021-00607-3 PMID: 34497402
  3. Liljeblad, A.; Kallinen, A.; Kanerva, L. Biocatalysis in the preparation of the statin side chain. Curr. Org. Synth., 2009, 6(4), 362-379. doi: 10.2174/157017909789108738
  4. Libby, P. The changing landscape of atherosclerosis. Nature, 2021, 592(7855), 524-533. doi: 10.1038/s41586-021-03392-8 PMID: 33883728
  5. Bakker-Arkema, R. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis, 1997, 131(1), 17-23. doi: 10.1016/S0021-9150(97)06066-8
  6. Grundy, S.M. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA, 1993, 269(23), 3015-3023. doi: 10.1001/jama.1993.03500230097036 PMID: 8501844
  7. Society, E.A. Prevention of coronary heart disease: Scientific background and new clinical practice guidelines. Nutr. Metab. Cardiovasc. Dis., 1992, 2, 113-156.
  8. Rosamond, W.D.; Chambless, L.E.; Folsom, A.R.; Cooper, L.S.; Conwill, D.E.; Clegg, L.; Wang, C.H.; Heiss, G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N. Engl. J. Med., 1998, 339(13), 861-867. doi: 10.1056/NEJM199809243391301 PMID: 9744969
  9. Kannel, W.B.; Castelli, W.P.; Gordon, T.; McNamara, P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann. Intern. Med., 1971, 74(1), 1-12. doi: 10.7326/0003-4819-74-1-1 PMID: 5539274
  10. Austin, M.A. Plasma triglyceride and coronary heart disease. Arterioscler. Thromb., 1991, 11(1), 2-14. doi: 10.1161/01.ATV.11.1.2 PMID: 1987999
  11. Hulley, S.B.; Rosenman, R.H.; Bawol, R.D.; Brand, R.J. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N. Engl. J. Med., 1980, 302(25), 1383-1389. doi: 10.1056/NEJM198006193022503 PMID: 7374696
  12. Pedersen, T.R. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S). Lancet, 1994, 344(8934), 1383-1389. PMID: 7968073
  13. Ferri, N.; Corsini, A. Clinical pharmacology of statins: An update. Curr. Atheroscler. Rep., 2020, 22(7), 26. doi: 10.1007/s11883-020-00844-w PMID: 32494971
  14. Corsini, A.; Maggi, F.M.; Catapano, A.L. Pharmacology of competitive inhibitors of HMg-CoA reductase. Pharmacol. Res., 1995, 31(1), 9-27. doi: 10.1016/1043-6618(95)80042-5 PMID: 7784310
  15. Azemawah, V.; Movahed, M.R.; Centuori, P.; Penaflor, R.; Riel, P.L.; Situ, S.; Shadmehr, M.; Hashemzadeh, M. State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications. Cardiovasc. Drugs Ther., 2019, 33(5), 625-639. doi: 10.1007/s10557-019-06904-x PMID: 31773344
  16. Moghadasian, M.H. Experimental atherosclerosis: A historical overview. Life Sci., 1999, 65, 1329. doi: 10.1016/S0024-3205(99)00199-X PMID: 10503952
  17. Khan, T.J.; Ahmed, Y.M.; Zamzami, M.A.; Siddiqui, A.M.; Khan, I.; Baothman, O.A.S.; Mehanna, M.G. kuerban, A.; Kaleemuddin, M.; Yasir, M. Atorvastatin treatment modulates the gut microbiota of the hypercholesterolemic patients. OMICS, 2018, 22(2), 154-163. doi: 10.1089/omi.2017.0130 PMID: 29432061
  18. Haque, T.; Khan, B.V. Atorvastatin: A review of its pharmacological properties and use in familial hypercholesterolemia. Clin. Lipidol., 2010, 5(5), 615-625. doi: 10.2217/clp.10.55
  19. Nawrocki, J.W.; Weiss, S.R.; Davidson, M.H.; Sprecher, D.L.; Schwartz, S.L.; Lupien, P.J.; Jones, P.H.; Haber, H.E.; Black, D.M. Perfusion, 1996, 9(3), 109-114.
  20. Best, J.D.; Nicholson, G.C. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diabetes Nutr. Metab., 1996, 9, 74-80.
  21. Ionica, F.E.; Pisoschi, C.; Negres, S.; Nikos, R.F.; Tarata, M.; Popescu, F. Atorvastain influence om glycemic control in patients with type 2 diabetes mellitus. Farmacia, 2010, 58(6), 728-734.
  22. Kougialis, S.; Skopelitis, E.; Gialernios, T.; Nikolaou, S.; Kroustalis, A.; Katsadorou, E.; Gialernios, K.; Zervou, A.; Gika, E.; Polydorou, A.; Polydorou, V.; Drakoulis, C.; Iliopoulos, N.; Dermitzakis, I.; Mpilinis, H.; Polydorou, A. Atorvastatin therapy is associated with improvement of oxidized low-density lipoprotein cholesterol levels, which correlates with the degree of stenosis in patients with carotid atheromatosis with and without prior angioplasty. Int. J. Angiol., 2010, 29(4), 338-347. PMID: 20671652
  23. Malhotra, H.S.; Goa, K.L. Atorvastatin. Drugs, 2001, 61(12), 1835-1881. doi: 10.2165/00003495-200161120-00012 PMID: 11693468
  24. Koh, K.K.; Quon, M.J.; Han, S.H.; Lee, Y.; Park, J.B.; Kim, S.J.; Koh, Y.; Shin, E.K. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol., 2011, 146(3), 319-325. doi: 10.1016/j.ijcard.2009.07.002 PMID: 19651449
  25. Jones, P.H.; Goldberg, A.C.; Knapp, H.R.; Kelly, M.T.; Setze, C.M.; Stolzenbach, J.C.; Sleep, D.J. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am. Heart J., 2010, 160(4), 759-766. doi: 10.1016/j.ahj.2010.06.045 PMID: 20934572
  26. Chawla, P.A.; Pandey, S. Various analytical methods for analysis of atorvastatin: A review. J. Drug Deliv. Ther., 2019, 9(3-s), 885-899.
  27. Kogawa, A.C.; Pires, A.E.D.T.; Salgado, H.R.N. Atorvastatin: A review of analytical methods for pharmaceutical quality control and monitoring. J. AOAC Int., 2019, 102(3), 801-809. doi: 10.5740/jaoacint.18-0200 PMID: 30563586
  28. Chong, P.H.; Seeger, J.D. Atorvastatin calcium: An addition to HMG-CoA reductase inhibitors. Pharmacotherapy, 1997, 17(6), 1157-1177. PMID: 9399600
  29. Althanoon, Z.; Faisal, I.M.; Ahmad, A.A.; Merkhan, M.M.; Merkhan, M.M. Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Syst. Rev. Pharm, 2020, 11(7), 167-171.
  30. Nováková, L.; Šatínský, D.; Solich, P. HPLC methods for the determination of simvastatin and atorvastatin. Trends Analyt. Chem., 2008, 27(4), 352-367. doi: 10.1016/j.trac.2008.01.013
  31. Hirota, T.; Fujita, Y.; Ieiri, I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin. Drug Metab. Toxicol., 2020, 16(9), 809-822. doi: 10.1080/17425255.2020.1801634 PMID: 32729746
  32. Zaheer, Z.; Farooqui, M.N.; Mangle, A.A.; Nikalje, A.G. Stability-indicating high performance liquid chromatographic determination of atorvastatin calcium in pharmaceutical dosage form. Afr. J. Pharm. Pharmacol., 2008, 2(10), 204-210.
  33. Hoffmann, M.; Nowosielski, M. DFT study on hydroxy acid-lactone interconversion of statins: The case of atorvastatin. Org. Biomol. Chem., 2008, 6(19), 3527-3531. doi: 10.1039/b803342k PMID: 19082153
  34. Lennernäs, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet., 2003, 42(13), 1141-1160. doi: 10.2165/00003088-200342130-00005 PMID: 14531725
  35. Kolars, J.C.; Lown, K.S.; Schmiedlin-Ren, P.; Ghosh, M.; Fang, C.; Wrighton, S.A.; Merion, R.M.; Watkins, P.B. CYP3A gene expression in human gut epithelium. Pharmacogenetics, 1994, 4(5), 247-259. doi: 10.1097/00008571-199410000-00003 PMID: 7894497
  36. Lau, Y.Y.; Okochi, H.; Huang, Y.; Benet, L.Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems. J. Pharmacol. Exp. Ther., 2006, 316(2), 762-771. doi: 10.1124/jpet.105.093088 PMID: 16258024
  37. Harrington, P.J. Pharmaceutical process chemistry for synthesis: Rethinking the routes to scale-up; John Wiley & Sons, 2011.
  38. Roth, B.D.; Arbor, A. Trans-6-2-(3- or 4-carboxamidosubstituted pyrrol-1-yl)alkyl-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 4681893A, 1987.
  39. Roth, B.D.; Arbor, A. R-(R* R*)-2-(4-fluorophenyl-β, δ- dihydroxy-5-(1-methylethyl-3-phenyl-4-(phenylamino) carbonyl-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof. U.S. Patent 5273995, 1993.
  40. Ye, J.; Liu, Y.; Li, C.L. Method for preparing atorvastatin calcium. C.N. Patent 101613312A, 2009.
  41. Roth, B.D.; Blankley, C.J.; Chucholowski, A.W.; Ferguson, E.; Hoefle, M.L.; Ortwine, D.F.; Newton, R.S.; Sekerke, C.S.; Sliskovic, D.R.; Wilson, M. Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-2-(1H-pyrrol-1-yl)ethyl-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J. Med. Chem., 1991, 34(1), 357-366. doi: 10.1021/jm00105a056 PMID: 1992137
  42. Guntoori, B.R.; Che, D.; Wang, F.; Zhao, Y.; Murthy, K.S.K.; Horne, S.E. An improved preparation of atorvastatin. W.O. Patent 087723A1, 2005.
  43. Guntoori, B.R.; Che, D.; Zhao, Y.; Murthy, K.S.K.; Horne, S.E. Preparation of atorvastatin. U.S. Patent 0203302A1, 2005.
  44. Bell, E.L.; Finnigan, W.; France, S.P.; Green, A.P.; Hayes, M.A.; Hepworth, L.J.; Lovelock, S.L.; Niikura, H.; Osuna, S.; Romero, E.; Ryan, K.S.; Turner, N.J.; Flitsch, S.L. Biocatalysis. Nat. Rev. Methods Primers, 2021, 1(1)
  45. Hoyos, P.; Pace, V.; Alcántara, A. Biocatalyzed synthesis of statins: A sustainable strategy for the preparation of valuable drugs. Catalysts, 2019, 9(3), 260. doi: 10.3390/catal9030260
  46. Butler, D.E.; Dejone, R.L.; Nelson, J.D. Novel process for the synthesis of 5-(4-fluorophenyl)-1-2-((2R,4R)-4- hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl-2-isopropyl-4- phenyl-1H-pyrrole-3-carboxylic acid phenylamide. U.S. Patent 20020133026A1, 2002.
  47. Fleige, M.; Glorius, F. α-unsubstituted pyrroles by NHC-catalyzed three-component coupling: Direct synthesis of a versatile atorvastatin derivative. Chemistry, 2017, 23(45), 10773-10776. doi: 10.1002/chem.201703008 PMID: 28666059
  48. Baumann, K.L.; Butler, D.E.; Deering, C.F.; Mennen, K.E.; Millar, A.; Nanninga, T.N.; Palmer, C.W.; Roth, B.D. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett., 1992, 33(17), 2283-2284. doi: 10.1016/S0040-4039(00)74190-6
  49. Butler, D.E. Process for trans-6-2-(substituted-Pyrrol-1-yl) alkyl pyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 5298627, 1994.
  50. Woo, P.W.K.; Hartman, J.; Huang, Y. Atorvastatin, an HMG-CoA reductase inhibitor and efficient lipid-regulation agent. J. Labelled Comp. Radiopharm., 1999, 42(2), 121-127. doi: 10.1002/(SICI)1099-1344(199902)42:23.0.CO;2-Z
  51. Niddam, V.; Hadas, R.L.; Lifshitz, R.; Ishai, E. Hydrolysis of R-(R* R*)-2-(4-fluorophenyl-β, δ-dihydroxy-5-(1- methylethyl-3-phenyl-4-(phenylamino) carbonyl-1Hpyrrole- 1-heptanoic acid esters with calcium hydroxide. U.S. Patent 6528661, 2003.
  52. Chen, B.C.; Sundeen, J.E.; Guo, P.; Bednarz, M.S.; Hangeland, J.J.; Ahmed, S.Z.; Jemal, M. Synthesis of deuterium-labeled atorvastatin and its metabolites for use as internal standards in a LC/MS/MS method developed for quantitation of the drug and its metabolites in human serum. J. Labelled Comp. Radiopharm., 2000, 43(3), 261-270. doi: 10.1002/(SICI)1099-1344(20000315)43:33.0.CO;2-T
  53. Stach, J.; Havlíček, J.; Plaček, L.; Rádl, S. Synthesis of some impurities and/or degradation products of atorvastatin. Collect. Czech. Chem. Commun., 2008, 73(2), 229-246. doi: 10.1135/cccc20080229
  54. Amarnath, V.; Amarnath, K.; Amarnath, K.; Davies, S.; Roberts, L.J. II Pyridoxamine: An extremely potent scavenger of 1,4-dicarbonyls. Chem. Res. Toxicol., 2004, 17(3), 410-415. doi: 10.1021/tx0300535 PMID: 15025512
  55. Patel, D.J.; Kumar, R.; Dwivedi, S.P.D. Process for the preparation of atorvastatin calcium. W.O. Patent 096751A1, 2007.
  56. Valerie, N.H.; Revital, L.L.; Rami, L.H. Process for preparing calcium salt forms of statins. U.S. Patent 6777552B2, 2004.
  57. Sullivan, S.O.; Neill, J.O. Preparation of an atorvastatin intermediate. U.S. Patent 0221839A1, 2009.
  58. Thottathil, J.K.; Pendri, Y.; Li, W.S.; Kronenthal, D.R. Process for the preparation of 1, 3-dioxane derivatives useful in the preparation of HMG-CoA reductase inhibitors. U.S. Patent 5278313, 1994.
  59. Thottathil, J.K.; Pendri, Y.; Li, W.S.; Kronenthal, D.R. Process for the preparation of 1, 3-dioxane derivatives useful in the preparation of HMG-CoA reductase inhibitors. U.S. Patent 5457227, 1995.
  60. Brower, P.L.; Butler, D.E.; Deering, C.F.; Le, T.V.; Millar, A.; Nanninga, T.N.; Roth, B.D. The synthesis of (4R-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane- 4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett., 1992, 33(17), 2279-2282. doi: 10.1016/S0040-4039(00)74189-X
  61. Rádl, S. A New Way to tert -Butyl (4 R, 6R)-6-Aminoethyl-2,2-dimethyl-1,3-dioxan-4-ylacetate, a key intermediate of atorvastatin synthesis. Synth. Commun., 2003, 33(13), 2275-2283. doi: 10.1081/SCC-120021507
  62. Li, Z.; Yang, H.; Liu, J.; Huang, Z.; Chen, F. Application of ketoreductase in asymmetric synthesis of pharmaceuticals and bioactive molecules: An update (2018-2020). Chem. Rec., 2021, 21(7), 1611-1630. doi: 10.1002/tcr.202100062 PMID: 33835705
  63. Butler, D.E.; Deering, C.F.; Millar, A.; Nanninga, T.N.; Roth, B.D. Process for trans-6-2-(substituted-pyrrol-1- yl)alkylpyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 5245047, 1993.
  64. Rádl, S.; Stach, J.; Hajicek, J. An improved synthesis of 1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dio-xane-4-acetate, a key intermediate for atorvastatin synthesis. Tetrahedron Lett., 2002, 43(11), 2087-2090. doi: 10.1016/S0040-4039(02)00175-2
  65. Thomas, T.; Poornaprajna, A.; Aswathanarayanappa, C.; Sridharan, M.; Ganesh, S. Process for stereoselective recution of β-ketoesters. U.S. Patent 7232920B2, 2007.
  66. Bosch, R.L.; Mscabe, R.J.; Nanninga, T.N.; Stach, R.J. Process for the synthesis of 1, 3-diols. U.S. Patent 7232915B2, 2007.
  67. Kooistra, J.H.M.H.; Zeegers, H.J.M.; Mink, D.; Mulders, J.M.C.A. Process for the preparation of 2-(6-substituted-1, 3-dioxane-4-yl) acetic acid derivatives. W.O. Patent 06266A1, 2002.
  68. Mitsuda, M.; Miyazaki, M.; Inoue, K. Process for producing 6-caynomethyl-1, 3-dioxane-4-acetic acid derivatives. U.S. Patent 6344569B1, 2002.
  69. Xiong, F.J.; Li, J.; Chen, X.F.; Chen, W.X.; Chen, F.E. An improved process for chiron synthesis of the atorvastatin side chain. Tetrahedron Asymmetry, 2014, 25(16-17), 1205-1208. doi: 10.1016/j.tetasy.2014.07.002
  70. Patel, J.M. Biocatalytic synthesis of atorvastatin intermediates. J. Mol. Catal., B Enzym., 2009, 61(3-4), 123-128. doi: 10.1016/j.molcatb.2009.07.004
  71. Kizaki, N.; Yamada, Y.; Yasohara, Y.; Nishiyama, A.; Miyazaki, M.; Mitsuda, M.; Kondo, T.; Ueyama, N.; Inoue, K. Process for producing optically active 2-6- (hydroxymethyl)-1, 3-dioxan-4-yl acetic acid derivatives. U.S. Patent 0040634A1, 2003.
  72. Yasohara, Y.; Kizaki, N.; Hasegawa, J.; Wada, M.; Kataoka, M.; Shimizu, S. Stereoselective reduction of alkyl 3-oxobutanoate by carbonyl reductase from Candida magnoliae. Tetrahedron Asymmetry, 2001, 12(12), 1713-1718. doi: 10.1016/S0957-4166(01)00279-8
  73. Kizaki, N.; Yasohara, Y.; Hasegawa, J.; Wada, M.; Kataoka, M.; Shimizu, S. Synthesis of optically pure ethyl (S)-4-chloro-3-hydroxybutanoate by Escherichia coli transformant cells coexpressing the carbonyl reductase and glucose dehydrogenase genes. Appl. Microbiol. Biotechnol., 2001, 55(5), 590-595. doi: 10.1007/s002530100599 PMID: 11414326
  74. Wolberg, M.; Filho, M.V.; Bode, S.; Geilenkirchen, P.; Feldmann, R.; Liese, A.; Hummel, W.; Müller, M. Chemoenzymatic synthesis of the chiral side-chain of statins: Application of an alcohol dehydrogenase catalysed ketone reduction on a large scale. Bioprocess Biosyst. Eng., 2008, 31(3), 183-191. doi: 10.1007/s00449-008-0205-9 PMID: 18288496
  75. Wolberg, M.; Hummel, W.; Müller, M. Biocatalytic reduction of β,δ-diketo esters: A highly stereoselective approach to all four stereoisomers of a chlorinated β,δ-dihydroxy hexanoate. Chemistry, 2001, 7(21), 4562-4571. doi: 10.1002/1521-3765(20011105)7:213.0.CO;2-4 PMID: 11757647
  76. Liu, J.; Hsu, C.C.; Wong, C.H. Sequential aldol condensation catalyzed by DERA mutant Ser238Asp and a formal total synthesis of atorvastatin. Tetrahedron Lett., 2004, 45(11), 2439-2441. doi: 10.1016/j.tetlet.2004.01.110
  77. Greenberg, W.A.; Varvak, A.; Hanson, S.R.; Wong, K.; Huang, H.; Chen, P.; Burk, M.J. Development of an efficient, scalable, aldolase-catalyzed process for enantioselective synthesis of statin intermediates. Proc. Natl. Acad. Sci., 2004, 101(16), 5788-5793. doi: 10.1073/pnas.0307563101 PMID: 15069189
  78. Davis, S.C.; Grate, J.H.; Gray, D.R.; Gruber, J.M.; Huisman, G.W.; Ma, S.K.; Newman, L.M.; Sheldon, R.; Wang, L.A. Enzymatic process for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters. W.O. Patent 018579A2, 2005.
  79. Dicks, P. Green chemistry and associated metrics.Green Chemistry Metrics; Springer: Cham, 2015, pp. 1-15.
  80. Giver, L.J.; Newman, L.S.; Mundorff, E.; Huisman, G.W.; Jenne, S.J.; Zhu, Z.; Behrouzian, B.; Grate, J.H.; Lalonde, J. Compositions and methods for produing stereoisomerically pure statins and synthetic intermediates therefor. U.S. Patent 0195465A1, 2011.
  81. Sawant, P.; Maier, M.E. A novel strategy towards the atorvastatin lactone. Tetrahedron, 2010, 66(51), 9738-9744. doi: 10.1016/j.tet.2010.10.028
  82. Mohammad, S.; Jitendra, S.; Yatendra, K.; Chander, A.R.; Krishna, R.V.; Anita, C. Substituted pyrrole derivatives. W.O. Patent 106299A2, 2004.
  83. John, M.D.; William, W.J. Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin. W.O. Patent 012246A, 2005.
  84. Norman, B.D. Novel process for trans-6-2-(Substituted- Pyrrol-1-Yl)AlkylPyran-2-one inhibitors of cholesterol synthesis. W.O. Patent 1994020492, 1994.
  85. Tararov, V.; Borner, A.; Konig, G.; Korostylev, A. Method for the production of statins. W.O. Patent 2006122644, 2006.
  86. Lee, H.W.; Kim, Y.M.; Yoo, C.L.; Kang, S-K.; Ahn, S.K. An efficient method for the large-scale synthesis of atorvastatin calcium. Biomol. Ther., 2008, 16(1), 28-33. doi: 10.4062/biomolther.2008.16.1.028
  87. Sumitra, S.; Joy, M.; Sandhya, U.; Madhavan, S.; Ganesh, S. A process for the synthesis of atorvastatin form V and phenylboronates as intermediate conmpounds. W.O. Patent 057274A1, 2002.
  88. Sumitra, S.; Joy, M.; Sandhya, U.; Madhavan, S.; Ganesh, S. Process for the synthesis of atorvastatin form V and phenylboronates as intermediate conmpounds. U.S. Patent 6867306B2, 2005.
  89. Tararov, V.I.; Andrushko, N.; Andrushko, V.; König, G.; Spannenberg, A.; Börner, A. Synthesis of the chiral side chain of statins - lactone versus lactol pathway. Eur. J. Org. Chem., 2006, 2006(24), 5543-5550. doi: 10.1002/ejoc.200600849
  90. Baisch, R.Ö. Pyrrole synthesis. W.O. Patent 2003044011, 2002.
  91. Estévez, V.; Villacampa, M.; Menéndez, J.C. Concise synthesis of atorvastatin lactone under high-speed vibration milling conditions. Org. Chem. Front., 2014, 1(5), 458-463. doi: 10.1039/C4QO00052H
  92. Menéndez, J.; Leonardi, M.; Estévez, V.; Villacampa, M. The Hantzsch pyrrole synthesis: Non-conventional variations and applications of a neglected classical reaction. Synthesis, 2019, 51(4), 816-828. doi: 10.1055/s-0037-1610320
  93. Goyal, S.; Patel, B.; Sharma, R.; Chouhan, M.; Kumar, K.; Gangar, M.; Nair, V.A. An efficient strategy for the synthesis of syn 1,3-diols via iterative acetate aldol reactions and synthesis of atorvastatin lactone. Tetrahedron Lett., 2015, 56(40), 5409-5412. doi: 10.1016/j.tetlet.2015.08.011
  94. Dias, L.C.; Vieira, A.S.; Barreiro, E.J. The total synthesis of calcium atorvastatin. Org. Biomol. Chem., 2016, 14(7), 2291-2296. doi: 10.1039/C5OB02546J PMID: 26795833
  95. Zarganes-Tzitzikas, T.; Neochoritis, C.G.; Dömling, A. Atorvastatin (Lipitor) by MCR. ACS Med. Chem. Lett., 2019, 10(3), 389-392. doi: 10.1021/acsmedchemlett.8b00579 PMID: 30891146
  96. Ertürk, S.; Sevinç Aktaş, E.; Ersoy, L.; Fıçıcıoğlu, S. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. J. Pharm. Biomed. Anal., 2003, 33(5), 1017-1023. doi: 10.1016/S0731-7085(03)00408-4 PMID: 14656592
  97. Chaudhari, B.G.; Patel, N.M.; Shah, P.B.; Patel, L.J.; Patel, V.P. Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of atorvastatin and ezetimibe from their combination drug products. J. AOAC Int., 2007, 90(6), 1539-1546. PMID: 18193730
  98. Patel, V.; Baldha, R.; Patel, D. Simultaneous determination of atorvastatin calcium and ezetimib by ratio spectra derivative spectrophotometry and reverse phase-high performance liquid chromatography. Asian J. Chem., 2010, 22(4), 2507-2511.
  99. Chaudhari, B.; Patel, N.; Shah, P. Reverse Phase HPLC method for determination of atorvastatin calcium in plasma. Chem. Pharm. Bull., 2007, 55(2), 241-246. doi: 10.1248/cpb.55.241 PMID: 17268096
  100. Mohammadi, A.; Rezanour, N.; Ansari Dogaheh, M.; Ghorbani Bidkorbeh, F.; Hashem, M.; Walker, R.B. A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 846(1-2), 215-221. doi: 10.1016/j.jchromb.2006.09.007 PMID: 17010681
  101. Nirogi, R.; Mudigonda, K.; Kandikere, V. Chromatography–mass spectrometry methods for the quantitation of statins in biological samples. J. Pharm. Biomed. Anal., 2007, 44(2), 379-387. doi: 10.1016/j.jpba.2007.02.008 PMID: 17433599
  102. Nováková, L.; Lopéz, S.A.; Solichová, D.; Šatínský, D.; Kulichová, B.; Horna, A.; Solich, P. Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins. Talanta, 2009, 78(3), 834-839. doi: 10.1016/j.talanta.2008.12.057 PMID: 19269437
  103. Bořek-Dohalský, V.; Huclová, J.; Barrett, B.; Němec, B.; Ulč, I.; Jelínek, I. Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study. Anal. Bioanal. Chem., 2006, 386(2), 275-285. doi: 10.1007/s00216-006-0655-3 PMID: 16924379
  104. Van Pelt, C.K.; Corso, T.N.; Schultz, G.A.; Lowes, S.; Henion, J. A four-column parallel chromatography system for isocratic or gradient LC/MS analyses. Anal. Chem., 2001, 73(3), 582-588. doi: 10.1021/ac0006876 PMID: 11217766
  105. Nirogi, R.V.S.; Kandikere, V.N.; Shukla, M.; Mudigonda, K.; Maurya, S.; Boosi, R.; Anjaneyulu, Y. Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Biomed. Chromatogr., 2006, 20(9), 924-936. doi: 10.1002/bmc.622 PMID: 16470513
  106. Bullen, W.W.; Miller, R.A.; Hayes, R.N. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J. Am. Soc. Mass Spectrom., 1999, 10(1), 55-66. doi: 10.1016/S1044-0305(98)00118-4 PMID: 9888185
  107. Jemal, M.; Ouyang, Z.; Chen, B.C.; Teitz, D. Quantitation of Atorvastatin and its bio-transformation products in human serum by HPLC with electro spray tandem mass spectrometry. Rapid Communi. Mass Spectrom., 1999, 13, 1003-1015.
  108. Hermann, M.; Christensen, H.; Reubsaet, J.L.E. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal. Bioanal. Chem., 2005, 382(5), 1242-1249. doi: 10.1007/s00216-005-3266-5 PMID: 15933849
  109. Mornar, A.; Damić, M.; Nigović, B. Separation, characterization, and quantification of atorvastatin and related impurities by liquid chromatography-electrospray ionization mass spectrometry. Anal. Lett., 2010, 43(18), 2859-2871. doi: 10.1080/00032711003763624
  110. Sherma, J. Review of HPTLC in drug analysis: 1996-2009. J. AOAC Int., 2010, 93(3), 754-764. doi: 10.1093/jaoac/93.3.754 PMID: 20629372
  111. Shirkhedkar, A.; Surana, S. Simultaneous densitometric TLC analysis of atorvastatin calcium and fenofibrate in the bulk drug and in pharmaceutical formulations. JPC J. Planar Chromatog. Modern TLC, 2009, 22(5), 355-358.
  112. Hiral, J.; Panchal, B.N.S.; Patel, N.J. Estimation of pitavastatin calcium in tablet dosage forms by column liquid chromatography and ultraviolet spectrophotometry. J. Planar Chromatog., 2009, 22(4), 265-271.
  113. Hancu, G.; Tomegea, D.; Popescu, G.; Barabas-Hajdu, E. The use of capillary electrophoresis in the simultaneous determination of fixed-dose combination drugs for cardiovascular diseases. Trends Pharmacol. Sci., 2020, 6(3), 221-230.
  114. Hefnawy, M.M.; Sultan, M.; Al-Johar, H. Development of capillary electrophoresis technique for simultaneous measurement of amlodipine and atorvastatin from their combination drug formulations. J. Liq. Chromatogr. Relat. Technol., 2009, 32(20), 2923-2942. doi: 10.1080/10826070903320681
  115. Guihen, E.; Sisk, G.D.; Scully, N.M.; Glennon, J.D. Rapid analysis of atorvastatin calcium using capillary electrophoresis and microchip electrophoresis. Electrophoresis, 2006, 27(12), 2338-2347. doi: 10.1002/elps.200500899 PMID: 16786480
  116. Landers, J.P. Clinical capillary electrophoresis. Clin. Chem., 1995, 41(4), 495-509. doi: 10.1093/clinchem/41.4.495 PMID: 7720237
  117. Nigović, B.; Damić, M.; Injac, R.; Kočevar Glavač, N.; Štrukelj, B. Analysis of atorvastatin and related substances by MEKC. Chromatographia, 2009, 69(11-12), 1299-1305. doi: 10.1365/s10337-009-1049-4
  118. Sharma, S.; Sharma, M.C. Determination of atorvastatin calcium and pioglitazone HCl in pharmaceutical formulations form by using atomic absorption spectrometry. Optoelectron. Adv. Mater. Rapid Commun., 2010, 4(8), 1196-1199.
  119. Sánchez Rojas, F.; Bosch Ojeda, C. Recent development in derivative ultraviolet/visible absorption spectrophotometry: 2004-2008. Anal. Chim. Acta, 2009, 635(1), 22-44. doi: 10.1016/j.aca.2008.12.039 PMID: 19200476
  120. Ayalon, A.; Levinger, M.; Roytblat, S.; Niddam, V.; Lifshitz, R.; Aronhime, J. Polymorphic form of atorvastatin calcium. U.S. Patent 7411075, 2008.
  121. Briggs, C.; Jennings, R.; Wade, R.; Harasawa, K.; Ichikawa, S.; Minohara, K.; Nakagawa, S. Crystalline R-(R*, R*)-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethy l)-3-phenyl-4-(phenylamino)carbonyl-1H-pyrrole-1- heptanoic acid hemi calcium salt (atorvastatin). U.S. Patent 005969156A, 1999.
  122. Lee, E.H. A practical guide to pharmaceutical polymorph screening & selection. Asian J. Pharmaceut. Sci., 2014, 9(4), 163-175. doi: 10.1016/j.ajps.2014.05.002
  123. Skorda, D.; Kontoyannis, C.G. Identification and quantitative determination of atorvastatin calcium polymorph in tablets using FT-Raman spectroscopy. Talanta, 2008, 74(4), 1066-1070. doi: 10.1016/j.talanta.2007.07.030 PMID: 18371751
  124. Mazurek, S.; Szostak, R. Quantification of atorvastatin calcium in tablets by FT-Raman spectroscopy. J. Pharm. Biomed. Anal., 2009, 49(1), 168-172. doi: 10.1016/j.jpba.2008.10.015 PMID: 19062220

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers